What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
Ruben A. Mesa spends much of his time researching Myelofibrosis, Internal medicine, Surgery, Myeloid and Polycythemia vera.
His Myelofibrosis research is multidisciplinary, incorporating perspectives in Essential thrombocythemia, Adverse effect and Anemia.
His work deals with themes such as Gastroenterology and Oncology, which intersect with Internal medicine.
His Surgery research focuses on Splenectomy and how it relates to Perioperative.
The concepts of his Myeloid study are interwoven with issues in Metaplasia, Myeloid leukemia, Bone marrow and Thrombocytosis.
His Polycythemia vera study incorporates themes from European LeukemiaNet and Intensive care medicine.
His most cited work include:
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2498 citations)
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis (1226 citations)
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis (892 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Myelofibrosis, Polycythemia vera, Ruxolitinib and Essential thrombocythemia.
His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine.
Ruben A. Mesa combines subjects such as Myeloid, Anemia and Constitutional symptoms with his study of Myelofibrosis.
Within one scientific family, Ruben A. Mesa focuses on topics pertaining to Transplantation under Polycythemia vera, and may sometimes address concerns connected to Stem cell.
His work in Ruxolitinib addresses subjects such as Adverse effect, which are connected to disciplines such as Discontinuation.
Ruben A. Mesa has researched Essential thrombocythemia in several fields, including Bone pain and Acute leukemia.
He most often published in these fields:
- Internal medicine (66.23%)
- Myelofibrosis (59.37%)
- Polycythemia vera (23.48%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.23%)
- Myelofibrosis (59.37%)
- Ruxolitinib (22.03%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Myelofibrosis, Ruxolitinib, Oncology and Gastroenterology.
When carried out as part of a general Internal medicine research project, his work on Myeloproliferative neoplasm, Polycythemia vera, Essential thrombocythemia and Quality of life is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Myelofibrosis research includes elements of Spleen, Anemia, Transplantation and Constitutional symptoms.
His Ruxolitinib study combines topics from a wide range of disciplines, such as Previously treated, Janus kinase inhibitor, Tolerability and Phases of clinical research.
Ruben A. Mesa usually deals with Oncology and limits it to topics linked to Cytopenia and Surrogate endpoint.
Ruben A. Mesa studied Gastroenterology and Adverse effect that intersect with Discontinuation.
Between 2018 and 2021, his most popular works were:
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea (47 citations)
- Oral Idasanutlin in Patients with Polycythemia Vera (28 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His primary areas of investigation include Internal medicine, Myelofibrosis, Ruxolitinib, Gastroenterology and Cohort.
His Internal medicine study frequently links to adjacent areas such as Oncology.
Myelofibrosis is a subfield of Bone marrow that Ruben A. Mesa investigates.
His Ruxolitinib research integrates issues from Thrombocytosis, Cancer research, Cell and Phases of clinical research.
As a part of the same scientific study, Ruben A. Mesa usually deals with the Gastroenterology, concentrating on Stem cell and frequently concerns with Toxicity and Combination therapy.
His Cohort research incorporates themes from Cancer, Clinical endpoint, Clinical trial, Absolute neutrophil count and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
